Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 LegoChem, Takeda Enter ADC Cancer Research Collaboration | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

LegoChem, Takeda Enter ADC Cancer Research Collaboration

Will focus on the development of antibody drug conjugates in immuno-oncology

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

LegoChem Biosciences has entered a research collaboration and license agreement with Takeda for the development of antibody-drug conjugates (ADCs) in immuno-oncology.
 
Takeda gains certain rights to LegoChemi’s ADC technology, ConjuAll, including its proprietary linker and conjugation platform, to research, develop and commercialize targeted immuno-oncology therapeutics. Under the terms of the agreement, Takeda has rights to use the LegoChem technology to develop therapeutics directed to up to three undisclosed targets.
 
LegoChem will receive $7.25 million in upfront and near-term milestone payments. In addition, LegoChem is eligible to receive development, regulatory and commercial milestone payments of up to $404 million as well as royalties on the sales of any resulting ADC products.
 
“We are delighted to collaborate with Takeda given its experience and expertise in oncology research and development. We believe this partnership provides further validation of our proprietary ADC platform technology that can be used for different oncology applications including immuno-oncology therapeutics,” said Yong-Zu Kim, chief executive officer, LegoChem Biosciences. “Our goal is to demonstrate the competitiveness of LegoChem in the global ADC market by applying our linker and payload platform technologies to our own and our collaborators’ pipelines.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics